EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast

Breast Cancer Research and Treatment

Volumn 79, Issue 2, 2003, Pages 187-198

  Lebeau, Annette ^a   Unholzer, Angela ^a   Amann, Gudrun ^a   Kronawitter, Michaela ^a   Bauerfeind, Ingo ^b   Sendelhofert, Andrea ^a   Iff, Anette ^a   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cell proliferation; Cyclin D1; DCIS; EGFR; HER 2 neu; p21; p53

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P21; PROTEIN P53; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL DIVISION; CHI-SQUARE DISTRIBUTION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; ONCOGENE PROTEINS V-ERBB; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038356604     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023958324448     Document Type: Article

References (68)

1. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
2. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines III GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG: Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20: 672-683, 2000
3. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589-23597, 1995
4. Aziz N, Cherwinski H, McMahon M: Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src. Mol Cell Biol 19: 1101-1115, 1999
5. Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). P Natl Acad Sci USA 95: 1091-1096, 1998
6. Gartel AL, Najmabadi F, Goufman E, Tyner AL: A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription. Oncogene 19: 961-964, 2000
7. Gjoerup O, Lukas J, Bartek J, Willumsen BM: Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation. J Biol Chem 273: 18812-18818, 1998
8. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Gene Dev 12: 3499-3511, 1998
9. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671, 1994
10. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994
11. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99, 1996
12. Pelosio P, Barbareschi M, Bonoldi E, Marchetti A, Verderio P, Caffo O, Bevilacqua P, Boracchi P, Buttitta F, Barbazza R, Dalla PP, Gasparini G: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7: 695-703, 1996
13. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW, Horne CH: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885-891, 1995
14. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Brit J Cancer 73: 728-734, 1996
15. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP: Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150: 705-711, 1997
16. Reed W, Florems VA, Holm R, Hannisdal E, Nesland JM: Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 435: 116-124, 1999
17. Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, Saegusa M, Okayasu I: Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin 125: 505-512, 1999
18. Barnes DM, Gillett CE: Cyclin D1 in breast cancer. Breast Cancer Res Tr 52: 1-15, 1998
19. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI, Sutherland RL: EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 17: 1053-1059, 1998
20. Spyratos F, Andrieu C, Vidaud D, Briffod M, Vidaud M, Lidereau R, Bieche I: CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer. Int J Biol Marker 15: 210-214, 2000
21. Iqbal M, Davies MP, Shoker BS, Jarvis C, Sibson DR, Sloane JP. Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells. J Pathol 193: 333-338, 2001
22. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Overexpression of cyclin D1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98: 415-418, 2002
23. Castro-Rivera E, Samudio I, Safe S: Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276: 30853-30861, 2001
24. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995
25. El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
26. Kivinen L, Tsubari M, Haapajarvi T, Datto MB, Wang XF, Laiho M: Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene 18: 6252-6261, 1999
27. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18: 4754-4765, 1999
28. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997
29. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC: Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2: 581-591, 1998
30. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59: 1347-1355, 1999
31. Reddy KB, Keshamouni VG, Chen YQ: The level of tyrosine kinase activity regulates the expression of p21/WAF1 in cancer cells. Int J Oncol 15: 301-306, 1999
32. Oh YL, Choi JS, Song SY, Ko YH, Han BK, Nam SJ, Yang JH: Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 51: 94-99, 2001
33. Bose S, Lesser ML, Norton L, Rosen PP: Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 120: 81-85, 1996
34. Fiche M, Avet-Loiseau H, Maugard CM, Sagan C, Heymann MF, Leblanc M, Classe JM, Fumoleau P, Dravet F, Mahe M, Dutrillaux B: Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes. Int J Cancer 89: 403-410, 2000
35. Glöckner S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H: Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness. Lab Invest 81: 565-571, 2001
36. Siziopikou KP, Schnitt SJ: MIB-1 proliferation index in ductal carcinoma in situ of the breast: relationship to the expression of the apoptosis-regulating proteins bcl- 2 and p53. Breast J 6: 400-406, 2000
37. Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, Van Zee KJ: In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 89: 2153-2160, 2000
38. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE: Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 151: 161-168, 1997
39. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU: Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary caminoma in situ. Am J Clin Pathol 97: S48-S52, 1992
40. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Engl J Med 319: 1239-1245, 1988
41. Bartkova J, Barnes DM, Millis RR, Gullick WJ: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21: 1164-1167, 1990
42. Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I: Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev 22: 313-318, 1998
43. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, Indelli M, Nenci I: Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer 83: 89-97, 1998
44. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS: Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75: 2123-2131, 1995
45. Gillett CE, Lee AH, Millis RR, Barnes DM: Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 184: 396-400, 1998
46. The Consensus Conference Committee: Consensus conference on the classification of ductal carcinoma in situ. Cancer 80: 1798-1802, 1997
47. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345: 1154-1157, 1995
48. Lagios MD: Duct carcinoma in situ. Pathology and treatment. Surg Clin N Am 70: 853-871, 1990
49. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Löhrs U: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354-363, 2001
50. De Potter CR, Van Daele S, van de Vijver MJ, Pauwels C, Maertens G, De Boever J, Vandekerckhove D, Roels H: The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 15: 351-362, 1989
51. Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, Kiang DT, Strickler JG: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23: 1141-1150, 1992
52. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X: Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 11: 208-214, 1994
53. Meyer JS: Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Tr 7: 171-180, 1986
54. Mack L, Kerkvliet N, Doig G, O'Malley FP: Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 28: 974-979, 1997
55. Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A: p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33: 39-44, 1997
56. Vos CB, ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJ: Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 187: 279-284, 1999
57. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021, 2001
58. Kim HJ, Jung WH, Kim DY, Lee HD: Expression of cyclins in ductal hyperplasia atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Yonsei Med J 41: 345-353, 2000
59. Alle KM, Henshall SM, Field AS, Sutherland RL: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4: 847-854, 1998
60. Umekita Y, Yoshida H: Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: an immunohistochemical study. Pathol Int 50: 527-530, 2000
61. Spitkovsky D, Steiner P, Gopalkrishnan RV, Eilers M, Jansen-Durr P: The role of p53 in coordinated regulation of cyclin D1 and p21 gene expression by the adenovirus E1A and E1B oncogenes. Oncogene 10: 2421-2425, 1995
62. Chen X, Bargonetti J, Prives C: p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 55: 4257-4263, 1995
63. Zhang H, Hannon GJ, Beach D: p21-containing cyclin kinases exist in both active and inactive states. Gene Dev 8: 1750-1758, 1994
64. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla PP, Harris AL: p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Brit J Cancer 74: 208-215, 1996
65. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180, 1994
66. Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der BB, Michalides RJ: Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol 16: 2554-2560, 1996
67. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12: 2315-2324, 1996
68. Foster JS, Henley DC, Ahamed S, Wimalasena J: Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metabiol 12: 320-327, 2001